3 best performing ASX shares in the week of 10 October 2022
Marc Kennis, October 17, 2022
The 3 best performing ASX shares in the week of 3 October 2022
The 3 best performing ASX shares of the week starting 10 October 2022 were Cettire (ASX:CTT), up 46.4%, Nova Eye Medical (ASX:EYE), up 42.5%, and Element 25 (ASX:E25), up 34.2%.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
1. Cettire (ASX:CTT)
Industry: Consumer Discretionary
Cettire Limited (ASX:CTT) is a global online retailer, offering a selection of in-demand personal luxury goods via its website, cettire.com. Cettire has access to a catalogue of over 1,700 luxury brands and over 190,000 products of clothing, shoes, bags and accessories.
Market Cap: $505m
12 month high / low: $0.33 – $4.81
2. Nova Eye Medical (ASX:EYE)
Industry: Healthcare
Nova Eye Medical Limited (ASX:EYE, formerly Ellex Medical Lasers Limited) is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices.
Market Cap: $42m
12 month high / low: $0.18 – $0.42
3. Element 25 (ASX:E25)
Industry: Resources
Element 25 Limited (ASX:E25, formerly Montezuma Mining Company Ltd) rounds out the top 3 best performing ASX shares this week. E25 is a mineral exploration and mining company exploring for manganese, copper and gold deposits in Western Australia. The Company has a 100% interest in Yamarna Gold Project, Butcherbird Manganese-Copper Project and Green Dam Project.
Market Cap: $159m
12 month high / low: $0.425 – $2.05
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
No credit card needed and the trial expires automatically.
Blog Categories
Get Our Top 5 ASX Stocks for FY25
Recent Posts
Telix Pharmaceuticals (ASX:TLX): It’s made ~A$1.7bn in revenue from Illucix, but here’s why the best is yet to come!
What would you have thought if you were told 5 years ago you would see Telix Pharmaceuticals as a successful…
Anti Woke ETFs: Do they practice what they preach and have they outperformed since Trump’s return to power?
Have you ever heard of so-called ‘Anti Woke ETFs’? If you’re sick of companies that are big on ESG, this…
Trump’s Tariffs Are Back in the News—What’s the Impact on Global Supply Chains?
In recent months, the conversation around trade tariffs has re-emerged, with former President Donald Trump’s trade policies making headlines once…